Burst Biologics researchers evaluated BioBurst Fluid, a cryopreserved umbilical cord blood-derived cellular allograft that is rich in growth factors, as well as cytokines and cells.
Researchers profiled UCB product from 33 donors to identify 44 quantifiable cytokines. They found UCB products elevated the proliferation and migration rates of mesenchymal stem cells and bone marrow stromal cells.
Additionally, researchers observed UCB product-induced secretion of Vegf-A, which promotes angiogenesis of endothelial cells, and osteoprotegerin, which promotes osteogenic differentiation of MSCs
Study authors conclude BioBurst Fluid is, “an excellent candidate for potential applications in orthopedic procedures like bone non-union and spinal fusion.”
The study accompanies two ongoing clinical trials of BioBurst Fluid for bone consolidation in spine as well as foot and ankle fusions.
Here is Burst Biologics’ spinal fusion registry, and here is the company’s foot and ankle registry.
More articles on biologics:
Orthobiologics market to reach $10.1B by 2025 — 6 key market players
Regenerative medicine company names Susan Vogt to board of directors: 3 notes
SpinalCyte’s CybroCell shows positive results for degenerative disc disease pain relief: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
